Takeda signed a multiyear discovery and technology collaboration with Iambic Therapeutics reportedly worth $1.7 billion, aiming to accelerate small‑molecule drug discovery across oncology, GI and inflammation targets. The deal gives Takeda access to Iambic’s generative and AI‑driven design tools while providing Iambic funding and validation to scale its platform. The pact reflects big‑pharma strategies to hedge internal R&D with external AI capabilities. Executives framed the arrangement as mutually reinforcing: Takeda gains computational discovery firepower; Iambic secures a large strategic partner to drive de‑risked preclinical programs toward clinical inflection points.